Jan C. Brase
Novartis (Switzerland)(CH)Bayer (Switzerland)(CH)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, HER2/EGFR in Cancer Research, Cytokine Signaling Pathways and Interactions, Chemokine receptors and signaling, Melanoma and MAPK Pathways
Most-Cited Works
- → Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers(2014)1,018 cited
- → Circulating miRNAs are correlated with tumor progression in prostate cancer(2010)586 cited
- → Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer(2018)574 cited
- → Serum microRNAs as non-invasive biomarkers for cancer(2010)419 cited
- → The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients(2013)347 cited
- → Loss of EpCAM expression in breast cancer derived serum exosomes: Role of proteolytic cleavage(2011)303 cited
- → ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy(2011)249 cited
- → EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer(2012)213 cited
- → HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis(2020)177 cited
- → Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial(2014)162 cited